Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Clin Cancer Res. 2011 Dec 6;18(3):858–868. doi: 10.1158/1078-0432.CCR-11-2121

Figure 1. ANZ-100 administration results in lymphocyte and natural killer (NK) cell declines in the peripheral blood suggesting margination into tissue and induces NK cell activation as evidenced by CD38 expression on CD3−CD16/56+ cells.

Figure 1

A, Measurement of lymphocytes in the peripheral blood shows transient lymphocyte declines following ANZ-100 administration. B, Measurement of NK cells in the peripheral blood shows transient NK cell declines following ANZ-100 administration. Legend refers to cohort dose level. C, CD38 expression on NK cells by cohort dose level. Ratio of peak CD38 MESF value between 48h and 96h post dosing and pre-dose value. A significant upregulation of CD38 was noted for all dose levels (p = 0.0008). There appears to be a slight dose-dependent trend but it was not statistically significant (p = 0.1238). D, Histogram showing CD38 expression on NK cells after ANZ-100 administration in subject 001–005.